Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

Summary by Enid News & Eagle
PASADENA, Calif.--(BUSINESS WIRE)--Jun 22, 2026-

2 Articles

Enid News & EagleEnid News & Eagle
Reposted by
stocktitan.netstocktitan.net
Lean Left

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

PASADENA, Calif.--(BUSINESS WIRE)--Jun 22, 2026-

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Monday, June 22, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

European Union icon

European Union

Pasadena, California icon

Pasadena, California

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal